암 면역치료 시장 규모, 점유율, 성장 분석 : 유형별, 용도별, 투여 경로별, 최종 사용자별, 지역별 - 업계 예측(2026-2033년)

Global Cancer Immunotherapy Market size was valued at USD 135.93 Billion in 2024 and is poised to grow from USD 147.35 Billion in 2025 to USD 280.92 Billion by 2033, growing at a CAGR of 8.4% during the forecast period (2026-2033).

The global Cancer Immunotherapy market is witnessing significant expansion driven by increasing cancer prevalence, a growing preference for targeted therapies, and advancements in immuno-oncology technologies. Immune checkpoint inhibitors, notably PD-1/PD-L1 and CTLA-4, are proving more effective than traditional treatments. Personalized medicine and CAR-T therapies are redefining treatment approaches, delivering sustainable results for various cancer types. Strong research and development efforts, coupled with favorable regulatory landscapes and enhanced public-private collaborations, are facilitating rapid innovation, especially for challenging malignancies like melanoma and lung cancer. However, high treatment costs, limited accessibility in low-income regions, and severe immune-related adverse effects pose considerable challenges. Nevertheless, the integration of artificial intelligence is revolutionizing patient selection and treatment optimization, ultimately aiming for more effective and equitable cancer care solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Immunotherapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Immunotherapy Market Segments Analysis

Global Cancer Immunotherapy Market is segmented by Type, Application, Route of Administration, End User and region. Based on Type, the market is segmented into Monoclonal Antibodies, Cancer Vaccines, Checkpoint Inhibitors and Immunomodulators. Based on Application, the market is segmented into Lung Cancer, Breast Cancer, Head and Neck Cancer, Prostate Cancer, Colorectal Cancer, Melanoma and Others. Based on Route of Administration, the market is segmented into Intravenous (IV), Intramuscular and Oral. Based on End User, the market is segmented into Hospitals & Clinics, Cancer Research Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Immunotherapy Market

The growth of the global cancer immunotherapy market is primarily driven by the increasing incidence of various cancer types across the globe. The escalating prevalence of cancer, which stands as a leading contributor to global health challenges, underscores the urgent demand for innovative and effective treatment methods. As cancers such as lung, breast, colorectal, melanoma, and blood-related malignancies continue to impact a significant portion of the population, the necessity for advanced therapeutic solutions becomes increasingly critical. This context emphasizes the importance of pioneering new strategies to tackle the rising global cancer burden and improve patient outcomes.

Restraints in the Global Cancer Immunotherapy Market

The rapid rise in cancer prevalence has intensified the focus on research and development in cancer treatments, particularly immunotherapy. As the production and testing of these therapies expand, the associated costs often become prohibitively high for patients, posing a significant barrier to market growth. Additionally, the various side effects linked with immunotherapy, including swelling, skin rashes, heart palpitations, and headaches, can deter patients from pursuing these treatments. This reluctance further undermines the potential expansion of the cancer immunotherapy market, highlighting the need to address both financial and safety concerns to foster wider acceptance and utilization of these therapies.

Market Trends of the Global Cancer Immunotherapy Market

A key market trend in the global cancer immunotherapy landscape is the increasing integration of personalized medicine strategies, as therapies are tailored to individual genetic profiles and tumor characteristics. This approach enhances treatment efficacy and minimizes adverse effects, driving demand for innovative biomarker-driven therapies. Additionally, the expansion of combination therapies, utilizing immunotherapies alongside traditional treatments like chemotherapy and targeted therapies, is gaining traction. The growing focus on addressing various cancer types and the rise of novel drug formulations, including CAR-T cell therapies and immune checkpoint inhibitors, are further shaping the market, leading to improved patient outcomes and heightened investment in research and development.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Cancer Immunotherapy Market Size by Type & CAGR (2026-2033)

• Market Overview
• Monoclonal Antibodies
• Cancer Vaccines
• Checkpoint Inhibitors
• Immunomodulators

Global Cancer Immunotherapy Market Size by Application & CAGR (2026-2033)

• Market Overview
• Lung Cancer
• Breast Cancer
• Head and Neck Cancer
• Prostate Cancer
• Colorectal Cancer
• Melanoma
• Others

Global Cancer Immunotherapy Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous (IV)
• Intramuscular
• Oral

Global Cancer Immunotherapy Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Cancer Research Centers
• Others

Global Cancer Immunotherapy Market Size & CAGR (2026-2033)

• North America (Type, Application, Route of Administration, End User)
  • US
  • Canada
• Europe (Type, Application, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, Route of Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zai Lab Limited (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fate Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kura Oncology, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations